Indexing

Uses of Myo-inositol and D-chiro-inositol for Management of PCOD

Author: Jain D., Khan W. and Singh S.

PDF Download PDF

Abstract

Polycystic ovarian disease, when diagnosed among women has been demonstrated to be associated with resistance to insulin with hyper-insulinemia. It is mainly due to deficiencies of Myo-inositol and D-chiro-inositol enriched Phosphoglycans which act as a mediator for insulin functioning. These medicinal agents normalize ovarian functioning, improvement of oocytes along with the quality of embryo in PCOD patients. The main challenge to the treatment of PCOS lies in its early detection in the young females. This can be overcome by conducting regular checkups and monitoring biochemical test results of LH/FSH ratio and fasting blood glucose in teenage females so classifying early symptoms can help in timely treatment of the disorder. This review article presents an overview of various published articles on the pathogenesis of PCOD, roles of Myo-inositol and D-chiro-inositol in regulating the pathophysiology and treating the condition without any hormone based intervention in both obese and non-obese female patients.

Keywords

PCOD, young females, Myo-inositol, D-chiro-inositol, insulin, obesity

Conclusion

Both Myo-inositol and D-chiro-inositol are insulin based secondary messengers. Myo-inositol influences the follicular gonadotropin pathway which assists ovulation. D-chiro-Inositol modulates release of androgen and helps in insulin signal transduction, while inhibiting ovarian aromatase synthesis. Inositols have proven to be effective in PCOS by improving metabolic and hormonal state, and restoring spontaneous ovulation. In assisted reproductive technology, inositols have revealed improvement of ovarian stimulation parameters, although data concerning fertility outcomes are conflicting. Given their functions, inositols are an attractive treatment option for PCOS, although ingenious studies on spontaneous and non-spontaneous fertility are needed.

References

-

How to cite this article

Jain D., Khan W. and Singh S. (2023). Uses of Myo-inositol and D-chiro-inositol for Management of PCOD. Biological Forum – An International Journal, 15(6): 329-332.